Accounting giant Ernst & Young will pay $4 million to settle civil charges that it violated auditor independence rules, U.S. regulators said.» Read More
The guys go behind the headlines and give you their take on ... JetBlue's CEO being forced out ... the latest company to miss earnings over milk prices ... and more.
Stocks sold off across the board, and the Dow fell almost 150 points, after mixed economic data prompted investors to book gains. "A day like today was inevitable," said Michael Cuggino of Permanent Portfolio Funds. "I would caution investors not to get overly concerned based on today's (economic) statistics."
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.
U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen and Johnson & Johnson , according to an agency document released on Tuesday.
Sears, Bank of New York, Amgen and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Actor Jonathan Tucker maintains his lead and fellow actor Stephen Collins holds on to second. Stephen was by far the most active celeb Tuesday (trust me, putting in all those ticker symbols for him was NOT easy), but his purchases could give him the lead if they perform well on Wednesday. Meanwhile, James Cromwell holds on to 3rd place, but Ernie Hudson falls from 4th place to 5th.
Actor Jonathan Tucker holds on to the top spot with a total portfolio value of $1,168,185.00 up $6,310.00 or 0.54% from Friday's total. But the real big news came from fellow actor Ernie Hudson. He climbed from 9th place on Friday to 4th Monday with a total portfolio value of $1,079,649.52--up $48,701.76 or 4.72% from Friday's total. Ernie added $45,701.76 to his total on the sale of Arch Coal (ACI) which was up 4.43% Monday.
Amgen, the world's largest biotechnology company, reported higher first-quarter profit on Monday, driven by increased sales of its anemia and arthritis drugs. Excluding items, the Thousand Oaks, Calif.-based company earned $1.08 a share, matching analysts' average forecast of $1.08 a share, according to Thomson Financial.
Amgen fools us: One of my favorite exercises at the Breaking News Desk is to figure out whether something is news, and how it might move the stock involved. This morning, a headline moved regarding Amgen’s anemia drug Aranesp. I’m not a pharmaceutical expert -- that’s why we have reporter Mike Huckman -- but since it involved a very large company and a drug I’d actually heard of, we knew it was news. Here’s where it got interesting...
Shares of Amgen surged after the biotech giant said that its anemia drug Aranesp showed no difference in risk of death compared with a placebo in a closely watched study of the medicine in small-cell lung cancer patients.
Stocks closed mixed but the Dow Jones Industrial Average inched up to another record as investors awaited key quarterly reports after the bell. "You still have some pretty important earnings coming out that are going to set the tone," said Adam Tracy, director of listed trading at Thomas Weisel Partners.
Earnings blowouts and encouraging drug trials were some of the catalysts behind Thursday's most actively traded stocks.
It was a volatile day for the celebs. Champion poker player Chris Moneymaker holds onto the first spot despite his $90K loss on Syntel but actor Jonathan Tucker takes over the #2 spot. Meanwhile, Willie Garson falls into 4th, allowing Stephen Collins to gain 3rd place. Johnny Bench falls from 6th to 8th. One of the stocks for Chris M., CBST, is also a favorite of Parker Robinson in our non-celeb trading. Both are "banking" on it paying off.
Champion poker player Chris Moneymaker widens his lead in first place to more than $150K with the sale of Adtran which was up 6.16% Tuesday--as actor Willie Garson lost over $20k on Seagate Technology--which was down 1.73% Tuesday. And actor Stephen Collins decided to take time off from his acting career--to make more buys and sells than everyone on Wall Street (I'm making this last sentence up--but as you will see, it's not that far off!).
Cramer's got the call on Bank of America, Jones Soda, AIG and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
World champ poker player Chris Moneymaker retains his lead in Trading With The Stars--though actor Willie Garson climbed back into second. Only about $10,000 separates the two. The balance between the two will hang on Monday's (today's) performance of Moneymaker's purchase of Rio Narcea Mines and Willie's buy of Mattel. AND Johnny Bench fought his way...
The National Kidney Foundation said on Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.
Genentech said first-quarter earnings surged 68% and reported quarterly earnings above expectations amid solid growth for blockbuster cancer drug Avastin. But sales of Lucentis, a treatment for age-related blindness, came up short.